Daniel Keizman

2.6k total citations
98 papers, 1.7k citations indexed

About

Daniel Keizman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel Keizman has authored 98 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 26 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel Keizman's work include Prostate Cancer Treatment and Research (49 papers), Radiopharmaceutical Chemistry and Applications (25 papers) and Renal cell carcinoma treatment (19 papers). Daniel Keizman is often cited by papers focused on Prostate Cancer Treatment and Research (49 papers), Radiopharmaceutical Chemistry and Applications (25 papers) and Renal cell carcinoma treatment (19 papers). Daniel Keizman collaborates with scholars based in Israel, United States and Spain. Daniel Keizman's co-authors include Maya Ish‐Shalom, Michael A. Carducci, Mario A. Eisenberger, Роберто Пили, Hans J. Hammers, Peng Huang, Fred M. Konikoff, Emmanuel S. Antonarakis, Maya Gottfried and Avivit Peer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Daniel Keizman

94 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Keizman Israel	23	1.0k	678	332	320	315	98	1.7k
Enrico Ricevuto Italy	24	465 0.5×	942 1.4×	379 1.1×	623 1.9×	129 0.4×	121	2.0k
G. Gorzegno Italy	21	440 0.4×	836 1.2×	249 0.8×	249 0.8×	251 0.8×	51	1.4k
Hao Long China	27	1.1k 1.0×	853 1.3×	565 1.7×	913 2.9×	231 0.7×	177	2.6k
Soichiro Funaki Japan	22	683 0.7×	616 0.9×	212 0.6×	346 1.1×	76 0.2×	146	1.7k
Sunhoo Park South Korea	22	453 0.4×	498 0.7×	201 0.6×	433 1.4×	318 1.0×	77	1.4k
Panagiotis J. Vlachostergios United States	21	683 0.7×	616 0.9×	370 1.1×	602 1.9×	207 0.7×	109	1.6k
Khaldoun Almhanna United States	27	1.1k 1.1×	982 1.4×	332 1.0×	596 1.9×	178 0.6×	168	2.5k
Juan C. Osorio United States	19	563 0.5×	641 0.9×	121 0.4×	473 1.5×	119 0.4×	44	1.7k
Klaus Baumann Germany	22	421 0.4×	1.0k 1.5×	247 0.7×	378 1.2×	325 1.0×	84	2.2k

Countries citing papers authored by Daniel Keizman

Since Specialization

Citations

This map shows the geographic impact of Daniel Keizman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Keizman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Keizman more than expected).

Fields of papers citing papers by Daniel Keizman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Keizman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Keizman. The network helps show where Daniel Keizman may publish in the future.

Co-authorship network of co-authors of Daniel Keizman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Keizman. A scholar is included among the top collaborators of Daniel Keizman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Keizman. Daniel Keizman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Dan, Charles Levine, David Sarid, et al.. (2023). Staging Prostate Cancer with⁶⁸Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?. Journal of Nuclear Medicine. 64(7). 1030–1035. 1 indexed citations

Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2023). Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study. Nutrients. 15(16). 3533–3533. 6 indexed citations

Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2023). P-MCP treatment in non-metastatic biochemically relapsed prostate cancer (BRPC-M0): Final long-term results of a prospective phase II study.. Journal of Clinical Oncology. 41(6_suppl). 162–162. 1 indexed citations

Kuten, Jonathan, Jeffrey Campbell, Yuval Bar‐Yosef, et al.. (2022). 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer. Canadian Urological Association Journal. 16(7). E381–E385. 11 indexed citations

Kuten, Jonathan, Charles Levine, David Sarid, et al.. (2021). Staging 68 Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement. European Journal of Nuclear Medicine and Molecular Imaging. 49(6). 2077–2085. 13 indexed citations

Drakaki, Alexandra, Michiel S. van der Heijden, Daniel P. Petrylak, et al.. (2019). Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer. 6(1). 43–52. 2 indexed citations

Heidenreich, Axel, Silke Gillessen, Daniel Heinrich, et al.. (2019). Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer. 19(1). 12–12. 33 indexed citations

Sartor, Oliver, Daniel Heinrich, Neil Mariados, et al.. (2017). Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Annals of Oncology. 28(10). 2464–2471. 21 indexed citations

Neiman, Victoria, Daniel Keizman, David Sarid, et al.. (2016). Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Annals of Oncology. 27. vi289–vi289.

10.

Sartor, Oliver, Daniel Heinrich, Neil Mariados, et al.. (2016). Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases. Annals of Oncology. 27. vi255–vi255. 1 indexed citations

11.

Saad, Fred, Axel Heidenreich, Daniel Heinrich, et al.. (2016). Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP). Annals of Oncology. 27. vi254–vi254. 1 indexed citations

12.

Procopio, Giuseppe, Stefano Severi, Elena Verzoni, et al.. (2016). Radium-223 (Ra-223) Re-treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC). Annals of Oncology. 27. iv30–iv30. 1 indexed citations

13.

Keizman, Daniel, Keren Rouvinov, Avishay Sella, et al.. (2015). Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?. Cancer Research and Treatment. 48(1). 281–287. 8 indexed citations

14.

Gottfried, Maya, Avivit Peer, Avivit Neumann, et al.. (2014). Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.. PubMed. 16(6). 347–51. 9 indexed citations

15.

González-Roibón, Nilda, Jaeyeon Kim, Sheila F. Faraj, et al.. (2014). Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. Urology. 83(6). 1444.e1–1444.e6. 24 indexed citations

16.

Keizman, Daniel, Maya Ish‐Shalom, Роберто Пили, et al.. (2012). Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. European Journal of Cancer. 48(7). 1031–1037. 42 indexed citations

17.

Keizman, Daniel, et al.. (2012). Metastatic Hormone Refractory Prostate Cancer. American Journal of Clinical Oncology. 37(3). 289–296. 7 indexed citations

18.

Keizman, Daniel & Mario A. Eisenberger. (2010). Is there a role for chemotherapy in nonmetastatic prostate cancer?. Current Opinion in Supportive and Palliative Care. 4(3). 141–146. 1 indexed citations

19.

Keizman, Daniel, Ori Rogowski, Shlomo Berliner, et al.. (2009). Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica. 119(6). 383–389. 80 indexed citations

20.

Keizman, Daniel, Maya Ish‐Shalom, & Fred M. Konikoff. (2006). An angulated common bile duct predisposes to recurrent symptomatic bile duct stones after endoscopic stone extraction. Surgical Endoscopy. 20(10). 1594–1599. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact